Ligand Pharmaceuticals competitors

Yvonne Greenstreet is a COO at ALNYLAM PHARMACEUTICALS, INC..

Mr. Gerard J. Michel has served as our Chief Financial Officer, Vice President of Corporate Development and Treasurer, since November 2007. Prior to joining Biodel, Mr. Michel served in various roles at NPS Pharmaceuticals, most recently as its Chief Financial Officer and Vice President of Corporate Strategy. Previously, Mr. Michel was a principal with the consulting firm of Booz-Allen & Hamilton where he evaluated and solved strategic and operational issues for healthcare clients. Mr. Michel also served in marketing, sales, and corporate development positions, both domestic and international with Lederle Labs. Mr. Michel received an M.S. in microbiology and an M.B.A., both from the University of Rochester.

Tom McCourt joined Ironwood as chief commercial officer and senior vice president of marketing and sales in 2009. He was drawn to Ironwood by the quality and values of the people and by the potential he saw in our first product. Since coming on board, Tom has designed and implemented Ironwood’s commercial strategy, leading the hiring of a sales force and bringing our first medicine to patients. Prior to joining Ironwood, Tom led the U.S. brand team for denosumab at Amgen Inc. Before that, he held a number of senior commercial roles with Novartis AG, where he directed the launch and growth of Zelnorm® (tegaserod maleate) for the treatment of patients with IBS‐C and chronic constipation and held a number of senior commercial roles, including vice president of strategic marketing and operations. Tom was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and serving as brand manager for Prilosec® (omeprazole). He has a degree in pharmacy from the University of Wisconsin.

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Howard Robin joined Nektar Therapeutics in January 2007. He has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. Most recently, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, asthma, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck for $1.1 billion. Prior to Sirna, Mr. Robin spent 20 years at Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG. From 1991 to 2001, he served as corporate vice president and general manager of their U.S. Therapeutics division and was responsible for the development of drugs, such as Betaseron® (Interferon beta-1b) for multiple sclerosis and Fludara® (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual global sales in excess of $800 million. He also served as a member of the Executive Committee. Prior to that, he was vice president of Finance and Business Development and CFO of Berlex. Earlier in his career, Mr. Robin was a senior associate with Arthur Andersen and Co. Mr. Robin serves as a director of the Biotechnology Industry Organization, the world's largest biotechnology industry trade organization. Mr. Robin holds a B.S. in Accounting and Finance from Fairleigh Dickinson University in New Jersey and serves as a member of its Board of Trustees.

Dr. Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the board of directors since the company’s inception. Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Dr. Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He was recognized as PharmaVoice’s 100 Most Inspiring People in 2009 and received the Dr. Sol J. Barer Award for Vision Innovation and Leadership in 2014. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.